Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-couple: Cryoablation with Camrelizumab and Apatinib in Advanced HCC
NCT04724226Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04724226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724226.